Key takeaways
- Bromelain is a pineapple-derived mixture of protein-cutting enzymes. Enzyme activity is real; reliable relief of everyday bloating or indigestion from a standalone supplement is not independently established (Biochemical evidence; Uncontrolled blend).
- A recent human ulcerative-colitis trial deserves attention, but its funding and product-supply terms remain incompletely disclosed. It is preliminary evidence, not a reason to replace treatment (Preliminary UC trial).
- Pineapple fruit, stem extracts, mixed-enzyme products and prescription burn-debridement gel are different interventions (Stem and fruit; Commercial blend; Topical label).
- Allergy is a documented concern. Stomach upset and diarrhea are reported; bleeding and drug-interaction warnings need careful separation of clinical evidence from laboratory theory (Oral effects; Allergy report; Experimental hemostasis).
- Milligrams alone do not describe enzyme potency. Activity units, source material, formulation and the complete ingredient list matter (Activity labeling).
Bromelain cleaves proteins, but the finite human evidence reviewed here does not establish dependable standalone relief of routine bloating or IBS. One small UC trial reported a symptom-score signal without a quality-of-life advantage or endoscopic confirmation. Its financing and product transactions remain unreported. Laboratory activity, a blend result and topical drug approval answer different questions; insufficient evidence does not prove ineffectiveness (Mechanism; Blend pilot; UC result; Protease blend).
This review checks both scientific design and reported financial relationships. Commercial involvement does not make a result false, and an academic or charitable label does not establish independence. Manufacturer-funded and incompletely disclosed studies are evaluated with their design limits; they do not provide an independently financed replication. Unknown product purchase or donation terms remain unknown.
Contents
Evidence summary · What it is · Forms and grades · How it works · Hype versus evidence · Benefits by claim · What works and what does not · Risks · Interactions · Who should avoid it · Studied doses · Laboratory evidence · Funding and independence · Regulatory status · FAQs · Sources and funding
Evidence summary
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Bromelain cleaves proteins | Biochemical assays distinguish stem and fruit mixtures | Hale 2005 | Broad IBD-0024R and NIH AT002288; product transaction terms unreported | Strong for tested mechanism; no symptom outcome |
| Routine bloating or indigestion | The cited pilot used a blend without placebo | Pellicano 2009 | Full original finances inaccessible | Insufficient standalone evidence in this review |
| Ulcerative colitis | 70 randomized; symptom signal, quality-of-life null, eight withdrawals | Delgarm 2025 | Manufacturer coded capsules; financing/supply terms unreported | Weak preliminary human signal |
| IBS | Company-funded five-ingredient GaRP study description; recruitment on hold | SAHMRI page | Anatara Lifesciences named funder | Insufficient bromelain-only result |
| Protein absorption | Ten analyzed; blend plus whey had no amino-acid advantage over whey alone | Townsend 2020 | Deerland funded; authors no conflicts | No added benefit detected in this acute blend study |
| Repairs permeability or improves the microbiome | Mouse and reconstructed-tissue experiments, not patient outcomes | Kostiuchenko 2022 | Public/charitable funding; tissue-model supplier affiliations | Preclinical only |
| Is harmless because it comes from fruit | Oral GI effects and human allergy reports exist | NCCIH, Nettis 2001 | Public guidance; case-report funding unknown | Safety concern established; incidence uncertain |
How grades work: Strong describes convincing evidence for the precise stated fact, such as a tested biochemical action. Weak describes a preliminary clinical signal. Insufficient means the reviewed evidence cannot establish the claimed use; it does not mean the intervention was conclusively disproved. Financial tiers below describe disclosed relationships separately from scientific strength.
What it is
Bromelain is obtained from Ananas comosus, the pineapple plant. The commercial name can refer to an extract containing several proteases rather than one uniform molecule. Stem-derived preparations and fruit-derived preparations have different enzyme profiles. The term “isolated bromelain” usually distinguishes an enzyme extract from whole pineapple; it does not guarantee one purified enzyme. Hale 2005
This article concerns oral supplements marketed for digestion and gut health. It does not evaluate every surgical, joint-pain or skin application, and it does not transfer success in those settings to the digestive tract.
Forms and grades
| Form or label feature | What it means | What it does not establish |
|---|---|---|
| Stem bromelain | Extract dominated by the stem enzyme | Equivalence to fruit bromelain (Stem profile). |
| Fruit bromelain, pineapple powder or juice | Different mixture and food matrix; processing matters | The dose or effect of a standardized capsule (Fruit and processing differences). |
| Single-ingredient capsule/tablet | Bromelain is the named active ingredient | One molecular species, or proven relief (Natural enzyme mixture). |
| Mixed digestive-enzyme or herbal formula | Other enzymes, antacids or botanicals may contribute | Which ingredient caused any observed change (Blend design; Commercial protease blend). |
| Enteric coating or targeted-release preparation | Changes where or when a preparation is released | Superior clinical outcomes without a direct comparison (Tested enteric preparation). |
| Milligrams plus activity units | Mass plus a laboratory estimate of catalytic activity | A guaranteed effect in a person’s digestive tract (Activity and mass). |
The stem/fruit distinction is supported by biochemical testing. Heat can inactivate activity, so a fresh-fruit experiment cannot simply be applied to a heat-processed pineapple food. Hale 2005
Health Canada’s digestive-enzyme monograph expresses quantity as enzyme activity; mass may be additional information. Products can use different recognized activity systems, so compare the named assay and activity per serving, not just a large number on the front label. Health Canada monograph
GDU and FCC PU measure activity; neither is a mass in milligrams. Health Canada provides an approximate GDU-to-FCC PU relation and requires recognized activity systems to be equivalent to the specified assay units. Such labeling does not establish clinical efficacy or equivalence to a particular trial. “Pharmaceutical grade,” “high potency” and “natural” are not trial outcomes (Activity specifications and Appendix I).
How it works
Proteases cut peptide bonds in proteins. That makes bromelain chemically relevant to digestion, but normal protein digestion already involves the body’s own enzymes. To establish a clinical advantage, a study must show an outcome such as less discomfort, better nutritional status or a meaningful change in a diagnosed disease. Measuring cleavage of a test substrate answers a narrower question (Assays establish cleavage, not patient relief; Pancreatic enzyme context).
Researchers exposed colon biopsies from people with IBD directly to bromelain outside the body and measured changes in selected inflammatory mediators. Not every cytokine decreased. These donors were not patients shown to improve after swallowing capsules, and the experiment did not measure symptom relief or mucosal healing (Actual biopsy Methods and Results).
This distinction matters whenever an advertisement says “studied in human intestinal tissue.” Human tissue outside the body is useful experimental material; it is not a human treatment trial (Ex vivo design).
Hype versus evidence
Three common shortcuts inflate this ingredient’s reputation:
- Digestive activity becomes digestive relief. Breaking down protein does not automatically reduce gas, urgency, pain or fullness. The cause of the symptom and the relevant food substrate still matter (Biochemical assay; Different symptom outcome).
- A combination becomes a single-ingredient result. A formula containing antacids, peppermint, another protease or pancreatic enzymes cannot establish bromelain’s contribution unless the design separates it (Uncontrolled combination; Blend crossover).
- Inflammation becomes a universal indication. A cell signal, postoperative swelling outcome or topical treatment cannot demonstrate that oral bromelain heals colitis or treats IBS (Tissue experiment; Topical route).
The same caution applies to an apparently large review. Pooling many unrelated diseases and preparations does not create a gut-specific result. A reviewer with no disclosed industry ties can still summarize manufacturer-funded underlying studies. This article therefore relies on the actual study and formulation, not the size or reassuring title of a review.
Benefits by claim
Everyday bloating, fullness and functional dyspepsia
Evidence grade: not independently established for standalone bromelain.
The primary abstract of a 2009 pilot reports 53 H. pylori-negative patients given TUBES gastro: sodium alginate, bicarbonate, bromelain and essential oils. Fifty-one completed and 35 reported improved symptom scores. There was no placebo arm and the design did not isolate bromelain. Complete original methods, numerical tables and financial/supply disclosures were not recovered (Accessible primary abstract).
A persuasive clinical test would compare a characterized standalone preparation with an appropriate control in a defined patient population, report meaningful symptoms and disclose financing and product sourcing. The finite studies assessed here do not provide dependable standalone evidence for routine digestive symptoms.
Ulcerative colitis
Evidence grade: preliminary human signal; independent efficacy unresolved.
The 2025 UC trial randomized 70 adults, 35 per group, to bromelain or placebo for eight weeks. Five active and three placebo participants withdrew; 30 and 32 completed. Reported intention-to-treat symptom-index changes were −3.29 versus −1.11 points, with no quality-of-life advantage. The main paper does not explain its missing-data handling; baseline sex balance differed. No endoscopy was performed. These scores do not demonstrate mucosal healing or a remission rate. Salamat Parmoon Amin manufactured and coded the capsules; cash financing and purchase/donation terms were not reported. The authors declared no competing interests (Complete original Methods, Tables 1/3 and disclosures).
This preliminary signal needs replication with transparent financing, objective disease measures and longer follow-up. It does not establish a replacement for UC care. Onken’s Introduction also describes the older Kane/Goldberg two-case report; that original letter was not recovered in this check. Uncontrolled improvement cannot isolate a supplement effect from other care or the disease course (Read secondary attribution; Original case-letter identity).
IBS, diarrhea and abdominal pain
Evidence grade: not independently established for bromelain alone.
GaRP combines bromelain, peppermint oil, L-threonine, sodium butyrate and vitamin D. SAHMRI names Anatara Lifesciences as the funder and currently states recruitment is on hold. The page describes the study, without reporting clinical outcomes. Academic recruitment and ethics oversight are separate from financial independence (Current official description and status).
Even a reliable GaRP result would concern that complete formulation unless the design separated its ingredients. No sponsor announcement is used here as a clinical outcome substitute. Animal or laboratory findings do not establish treatment of human IBS or infectious diarrhea.
Protein absorption and pancreatic insufficiency
Evidence grade: not independently established as a standalone supplement benefit; not an established substitute for pancreatic enzymes.
The ProHydrolase crossover recruited 12 people and analyzed ten after two scheduling withdrawals. It added 250 mg of a bacterial-protease/bromelain blend to 26 g whey after exercise. No amino-acid concentration timepoint or area-under-the-curve advantage over whey alone was found. Deerland Enzymes funded the study; authors declared no conflicts. This acute mixed-product experiment does not isolate bromelain or test digestive symptoms, malnutrition or pancreatic disease (Complete original design/results and back disclosures).
EPI requires diagnosis and clinician-directed care. NIDDK describes prescribed pancreatic enzyme replacement therapy, taken with food under clinical instructions. Bromelain’s protein-cleaving mechanism does not establish an alternative to that treatment (EPI overview; Actual PERT treatment instructions).
Microbiome balance, “leaky gut,” Crohn’s disease and colon-cancer prevention
Evidence grade: preclinical hypotheses, not established clinical benefits.
Mouse microbiome findings and tissue-barrier experiments do not demonstrate improved health in people. Particularly important, high experimental concentrations increased permeability in a reconstructed intestinal model; that is not evidence that bromelain “seals” the gut. It is also not proof that normal supplement exposure damages a human intestine. Dose, preparation and experimental setting determine what the result can support. Kostiuchenko 2022
Fresh pineapple juice reduced inflammation and associated neoplasia in specialized colitis-prone mice. In the same paper, daily stem bromelain did not sustain the long-term benefit. Juice and stem exposures differed. Neither experiment establishes human cancer prevention, Crohn’s treatment or capsule-equivalent food effects (Original animal comparisons).
What works and what does not
| Question | Best-supported answer |
|---|---|
| Does active bromelain cut protein? | Yes, in biochemical systems (Actual biochemical assays). |
| Does that prove a capsule helps post-meal symptoms? | No; a relevant human clinical comparison is needed (Symptom-study limit). |
| Does the recent UC trial settle the question? | No; preliminary results and unresolved independence require confirmation (Preliminary UC endpoints). |
| Can a digestive blend establish bromelain’s benefit? | Not unless the study separates the ingredient’s contribution (Blend design). |
| Can it replace prescribed pancreatic enzymes or IBD treatment? | No evidence establishes that use (PERT clinical care; UC limitations). |
| Does approval of a bromelain-derived burn gel validate supplements? | No; route, formulation and indication differ (Topical indication). |
| Has bromelain been conclusively shown never to help digestion? | No; insufficient evidence and proven ineffectiveness are different conclusions (Pilot limitations; Finite preliminary trial). |
This table summarizes the claim-level assessments above. It is not a product ranking.
Risks and adverse effects
| Aspect | Finding | Source |
|---|---|---|
| Gastrointestinal tolerance | Stomach upset and diarrhea are among the commonly reported oral adverse effects | NCCIH |
| Immediate allergy | Original case title reports IgE-mediated allergy; full clinical details were not recovered | Nettis 2001 |
| Contact-type reaction | Original case title reports allergic contact cheilitis; complete clinical details were not recovered | Raison-Peyron 2003 |
| Bleeding concern | Platelet and coagulation effects have experimental support; the size of any oral clinical risk is not established | Metzig 1999 |
| Pregnancy and breastfeeding | Human safety information is insufficient | NCCIH |
| Long-term or high-dose use | Short studies cannot establish lifelong safety or a universal safe maximum | Health Canada duration cautions |
| Diseased or injured GI tissue | The regulator advises assessment before use with GI lesions/ulcers | Health Canada |
Stop a product after a suspected allergic reaction and obtain medical advice. Breathing difficulty, throat swelling or faintness can indicate anaphylaxis and needs emergency help. Vomiting blood or black, tarry stools need urgent assessment. Persistent or severe digestive symptoms should be assessed clinically. Small studies cannot establish zero risk (Oral allergy precaution; Emergency allergy guidance; GI bleeding guidance).
Interactions: documented findings versus plausible concerns
| Substance or condition | Mechanism or concern | Severity/status | Source and gaps |
|---|---|---|---|
| Anticoagulants, antiplatelet drugs and anti-inflammatory medicines | Possible additive effects on clotting or bleeding | Potentially consequential; clinical magnitude uncertain. Seek professional review before combining | Human-platelet/rat experiment; regulatory caution. Laboratory action is not an oral bleeding rate |
| Tetracycline | An older proposed absorption interaction | One small negative comparison; no universal increase or all-dose safety estimate | Ten volunteers received 500 mg tetracycline with/without 80 mg enteric bromelain; absorption/elimination differences were not significant. Sequence/randomization and financial/supply terms were not reported (Original publisher citation; Actually read NLM scans). |
| Medicines metabolized by CYP2C9 | Inhibition in human liver microsomes | Laboratory signal; clinical relevance and exposure threshold unknown | Hidaka 2008. No clinical drug-level prediction can be made from this experiment |
| Surgery or a bleeding disorder | Uncertain hemostatic effects matter more in a vulnerable setting | Precaution, not a quantified risk estimate | Health Canada. The treating team should decide perioperative management |
| Other ingredients in the same product | Separate ingredient-specific allergies, absorption effects or interactions | Depends on the complete formulation | Review all active and inactive ingredients; bromelain-only findings do not clear a blend |
The complete 1978 letter did not find a significant tetracycline absorption advantage with 80 mg bromelain in ten volunteers. This limited within-person comparison does not prove that every dose, antibiotic or patient is unaffected. It does not justify using bromelain to alter prescribed antibiotic exposure (Original citation; Complete official original scans).
The primary abstract of an observational perioperative report describes 260 surgical patients receiving bromelain or diclofenac alongside low-molecular-weight heparin. It reports no increased hemorrhage signal, but was not randomized. Complete original methods/results, funding and product-supply disclosures were not recovered; it does not clear all anticoagulant combinations (Accessible primary abstract).
Who should avoid it or obtain a clinical review first
- People with a known bromelain or pineapple allergy should avoid self-exposure (Allergy stop instruction; Pineapple contraindication: topical context).
- People taking blood thinners, antiplatelets or anti-inflammatory medicines, or facing surgery, need a medication and bleeding-risk review (Blood-thinner/anti-inflammatory/surgery precautions).
- People with GI ulcers or lesions, active bleeding, or an unexplained persistent digestive problem should get assessed before trying it (GI lesions precaution; Bleeding evaluation).
- Pregnancy, breastfeeding and childhood are not settings in which adult supplement studies establish safety (Pregnancy/breastfeeding gap; Adult label scope).
- People with IBD or pancreatic insufficiency should not replace effective treatment with a retail enzyme (Prescribed EPI treatment; UC experiment limitations).
These are precautions and limits of evidence, not proof that every listed combination causes harm. The prescription bromelain-derived burn product also flags papain/papaya cross-sensitivity, but its topical label cannot quantify the allergy risk from an oral supplement. NEXOBRID label
Dosage: what was studied, not what to take
| Use case | Studied dose | Duration | Notes: research, not a prescription |
|---|---|---|---|
| UC trial | 200 mg/500 GDU twice daily | 8 weeks | Formulation-specific; independence unresolved; Delgarm |
| Dyspepsia pilot | 0.80 g combination tablets twice daily | At least 3 months | Total product mass, not bromelain dose; Pellicano |
| Post-exercise protein study | 250 mg protease blend with 26 g whey | Acute crossover visits | Blend dose, not isolated bromelain; sponsor-funded; Townsend |
| Tetracycline interaction experiment | 80 mg enteric-coated bromelain | Single-dose comparisons | Drug-interaction research, not a gut-health regimen; Bradbrook (Complete letter protocol). |
| Routine bloating, IBS or “gut repair” | No independently validated standalone regimen identified | Not established | A retail label is not a clinically established dose (Blend only; Different experimental setting). |
There is no defensible way to turn this table into a personalized dose schedule. Different activity assays, extracts, coatings and combinations are not automatically equivalent. A regulatory maximum is also not a target dose or evidence of benefit at that amount (Activity/duration and label limits).
Animal and laboratory evidence excluded from the benefit verdict
Research explains why bromelain is interesting, while also showing why broad promises are premature:
- Colon biopsies: direct exposure altered inflammatory mediator secretion. The NIH/Broad-supported work did not test symptom relief after oral treatment. Onken
- Pineapple juice in colitis-prone mice: a food intervention in a specialized animal model, not a supplement efficacy trial in people. Hale
- Mouse digestion and reconstructed human tissue: short-term animal changes and concentration-dependent barrier effects. The enzyme and tissue were purchased; two authors were affiliated with the tissue-model supplier, MatTek. That indirect commercial interest is disclosed despite a no-conflicts statement. Kostiuchenko
- The Bromeyal simulated-digestion and cell study received IRCCS Burlo Garofolo and Giellepi support. An author advised Giellepi, which supplied the preparation; Bict srl provided technical support. Supply payment/donation terms were not stated. Its laboratory findings do not establish patient benefit (Original citation; Complete original disclosures).
A proposed mechanism is neither meaningless nor sufficient. It helps define a clinical experiment; it cannot substitute for that experiment.
Funding, ownership and independence
Research funding at a glance
24 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

What the money trail does and does not show
Bromelain is an ingredient category, not a single company. Extractors, formulators, brand owners and retailers can profit from selling it; ownership and manufacturing location must be checked for the particular product. A plant’s origin, a company’s headquarters and a capsule’s manufacturing country are separate facts.
The most relevant documented commercial connections here are:
- Deerland Enzymes funded the ProHydrolase trial. ADM’s official 2022 annual report records acquisition of Deerland in 2021. The later ownership relationship does not establish that ADM funded the earlier trial (Original trial funding; Historical filing; current access limit; Actually read official acquisition record).
- Anatara Lifesciences funded the GaRP study described by SAHMRI in Australia. Recruitment is on hold on that page, which contains no clinical result report (Current primary description).
- Giellepi co-supported the Bromeyal laboratory study and supplied its preparation; an author was a scientific adviser. Bict srl, Lodi, provided technical support. The original does not report whether materials were donated or purchased (Original citation; Actual complete acknowledgments).
- Salamat Parmoon Amin → UC trial: documented manufacturing/coding role; financing and donation status remain unknown. Primary paper
- NIH and the Broad Medical Research Program supported the Duke biochemical and biopsy work. The 2010 mouse paper separately names NIH and American Institute for Cancer Research grant 06A057. Broad’s own history links its founders to KB Home and SunAmerica; that history does not establish a bromelain stake or verify its full investment portfolio (Biochemical acknowledgments; Biopsy acknowledgments; Mouse-paper AICR and NIH support; Primary foundation history).
Documented funding and commercial relationships are summarized above; unknown supply terms remain explicitly marked.
Funding interpretation: The relationships described above reflect documented funding, ownership or operational links. They do not assert hidden influence or wrongdoing. No unverified ownership percentage is supplied. Ultimate owners of the Iranian supplier and the complete commercial supply chains were not established in this review.
Source-credibility scorecard
Tier 1 means no identified ingredient-related financial stake after the stated checks; Tier 2 means indirect ties; Tier 3 means an interested party; Tier 4 means direct maker/seller funding or promotion. U means unresolved, not independent. A–D rates fitness and incentives for the stated use, not whether a result must be true. B-U is provisional because disclosures remain incomplete.
| Source | Funding/revenue and country | Tier; credibility | Accuracy incentives and remaining gaps |
|---|---|---|---|
| Hale 2005 biochemical paper | Broad IBD-0024R and NIH AT002288; Duke, US | U for procurement; B for tested chemistry | Complete main original read; suppliers obtained, transaction terms and individual disclosure absent (Actual original citation). |
| Delgarm 2025 UC trial | Iranian universities; Tehran manufacturer coded capsules; no funding statement | U; C provisional | Complete original main read; attrition/missing-data and financing/procurement reporting limits (Original). |
| Kane/Goldberg 2000 letter | Chicago report identity, US; financial support unverified | U; C provisional | Original full cases not recovered; two-case account is secondary attribution in Onken (Original identity; Read secondary account). |
| Pellicano 2009 pilot | Turin university/hospital, Italy; study support and product transactions unknown | U; C provisional | Complete primary abstract only; uncontrolled blend, full methods/COI inaccessible (Original abstract). |
| Townsend 2020 trial | Deerland Enzymes funding; US | 4; C | Authors no conflicts; no whey-alone amino-acid advantage; supply terms unreported (Full original). |
| SAHMRI GaRP page | Anatara Lifesciences funded; Australia | 4 for this study; C | Recruitment on hold; no outcomes on this descriptive page (Current source). |
| Kostiuchenko 2022 experiments | Swedish foundations and EU ERDF/ESF support; Sweden-led, Ukraine/Slovakia/Czech Republic affiliations | 2; B | Purchased materials and explicit grants; MatTek author affiliations create a tissue-platform interest |
| Onken 2008 biopsies | NIH/NCCAM AT002288 and Broad IBD-0024R; Duke, US | U for transactions; B for ex vivo evidence | Actual accepted main manuscript read; Sigma material listed, purchase/gift terms and individual conflict statement unreported (Original manuscript). |
| Hale 2010 mouse study | AICR 06A057 and NIH CA115480; Duke, US | U for remaining procurement; B for animal comparison | Pineapples purchased; Sigma stem material obtained, terms not stated. Long-term stem result null (Actual main manuscript). |
| Bottega 2021 laboratory study | IRCCS Burlo Garofolo, Giellepi and Bict technical support; Italy | 4; C | Giellepi supplied preparation; adviser tie; purchase/donation and budget terms unknown (Original citation; Full original). |
| Nettis 2001 allergy case | Bari academic affiliation, Italy; study support unknown | U; B-U | Useful adverse-event signal; cannot estimate frequency; full disclosure unavailable |
| Raison-Peyron 2003 cheilitis case | French clinical report; support unknown | U; B-U | Specific safety signal; no population risk estimate |
| Metzig 1999 platelets/animals | German academic report; funding/supply unknown | U; B-U | Primary mechanistic data; not a human oral interaction trial |
| Bradbrook 1978 letter | Guy’s Hospital Medical School, UK; no funding, conflict or supplier declaration in letter | U; B for limited within-person evidence | All three original page scans read; no significant interaction at tested dose, sequence unreported (Original citation; Full NLM original). |
| Hidaka 2008 microsomes | Japanese academic institutions; bromelain purchased from Sigma-Aldrich; funding unreported | U; B-U | Testable biochemical mechanism; not clinical interaction evidence |
| Johann 2011 perioperative report | German clinical report; full disclosures unverified | U; B-U | Observational clinical context; not independent safety clearance |
| NCCIH bromelain information | US federal agency, publicly funded | 1 for guidance; A for safety context | Public accountability; a summary can lag newer trials and is not itself a trial |
| NIDDK EPI information | US federal agency, publicly funded | 1 for guidance; A | Expert-reviewed patient guidance; not a bromelain study |
| Health Canada monograph | Canadian federal regulator, public regulatory role | 1 for rules; A | Specifies permitted labels and cautions; not a comprehensive independent efficacy review |
| FDA food/supplement guidance | US federal regulator; appropriations and industry user fees | 2 for institutional industry-fee ties; A for legal scope | Legal accountability; regulatory guidance is not independent drug-outcome evidence (Source-specific primary record). |
| NEXOBRID prescribing information | Manufacturer-origin regulated drug label, hosted by FDA; US regulatory jurisdiction | 4; C for route, indication and warnings | Legally accountable product labeling; no inference of oral digestive efficacy |
| GAO 2026 FDA funding audit | US legislative-branch public oversight | 1; A for funding facts | Audit accountability; institutional oversight priorities; no bromelain outcomes |
| ADM company acquisition disclosure | US commercial issuer, ingredient/agricultural revenue | 4; C for ownership role | Historical SEC route blocked; actual official 2022 report Note 3 verifies 2021 Deerland acquisition (Historical filing; Read issuer report). |
| Broad Foundation history | US private philanthropy; founders’ business wealth and invested assets | U for full financial chain; B for history | Primary founder/program history read; complete investments and upstream private grants unknown (Official account). |
Country concentration matters here: US guidance and US laboratory work are prominent, the contemporary monotherapy UC trial is Iranian, and the commercial blend program is Australian. This is not a geographically broad set of independently replicated clinical trials. Nationality is not a quality score.
Regulatory status
United States: supplements and food uses
FDA does not approve dietary supplements for safety and effectiveness before marketing. A supplement’s retail sale therefore does not establish treatment efficacy. Consumers should review medicines and health conditions with a healthcare professional (Actually read consumer guidance).
FDA’s food-substances record lists bromelain and links 21 CFR 184.1024 for technical food uses. This record is not approval to treat bloating, IBS or IBD; the complete separate CFR conditions were not assessed here (Actual food-substances record).
A prescription burn treatment is a different product
NEXOBRID (anacaulase-bcdb) is a topical proteolytic-enzyme drug for removal of burn eschar. The FDA label includes adults and pediatric patients. It is not an oral digestive supplement, and its approval cannot be used as a shortcut to a gut-health claim. FDA prescribing information
Canada: a monograph claim is not a trial result
The June 2026 digestive-enzyme monograph includes bromelain and protein-digestion uses. It explicitly describes a licensing/labeling guide rather than a comprehensive ingredient review. Its existence does not settle the independent clinical question addressed here. Health Canada
FAQs
Does eating pineapple do the same thing as taking bromelain?
No equivalence has been established. The food matrix, enzyme mixture, processing and activity differ. Pineapple can be food without being treated as a measured enzyme therapy (Preparation distinctions).
Is “500 mg” enough information to compare products?
No. It describes mass. Enzyme activity per serving, assay, plant part and other ingredients are needed to interpret the product. Those details still do not prove symptom relief (Activity units).
Does bromelain help digest lactose or prevent milk allergy?
Bromelain is a protease, not lactase. A claim about protein cleavage cannot establish lactose digestion, and it does not show that an allergenic food is safe to eat (Protein-cleaving specificity; Separate enzyme categories).
Does the UC trial mean IBD is now an established use?
No. It is a research signal that needs independent replication and stronger disease outcomes. People with IBD should keep treatment decisions with their clinical team (Preliminary endpoints).
Does bromelain definitely cause bleeding?
That overstates the evidence. A plausible mechanism warrants caution, particularly with medicines or a bleeding disorder, but a reliable oral risk estimate has not been established. Uncertainty is also not proof of safety (Experimental platelet evidence; Abstract-only observational boundary).
Should it be taken with food or on an empty stomach?
For digestive-use labeling, Health Canada specifies taking these enzymes with or immediately before food. Other clinical protocols used different timing and formulations. Follow the exact product label and prescriber instructions; research timing is not a universal treatment regimen for gut symptoms (Actual timing guidance; Different UC protocol).
What evidence would change this verdict?
Replicated, independently financed trials of a well-characterized standalone preparation, with purchased or transparently disclosed supplies, adequate adverse-event monitoring and patient-important endpoints. For IBD, objective inflammatory and healing outcomes would be especially useful.
Sources and funding notes
The linked sources serve different purposes: original clinical or laboratory experiments, primary metadata where an original remains inaccessible, and official clinical/regulatory/financial records. Financial disclosures identify relationships and do not validate advertised outcomes. Unknown support or material terms remain unknown.
Complete relevant main original sections and disclosures were personally read for the UC paper, ProHydrolase, mouse/tissue experiments, Duke biochemical/biopsy and pineapple work, CYP2C9 and Bromeyal. All three official original scans of Bradbrook’s tetracycline letter were read. The dyspepsia and perioperative reports remain abstract-only; older allergy and UC letters were not fully recovered. Private budgets, procurement and some individual conflicts remain unresolved even where full papers were read.
This is a structured assessment of the finite linked evidence, with explicit formulation, route, outcome and financial limits. It is not a registered systematic review or proof that no unpublished or inaccessible study exists.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
